Invest a sum of $10,000 in the Cathie Wood's dividend stock to potentially earn $2,000 over a span of five years through passive income.
In the realm of pharmaceutical giants, AbbVie stands out as a promising dividend growth stock for income-oriented portfolios. With a market capitalisation of approximately $254 billion, the company has demonstrated a robust commitment to rewarding shareholders through consistent dividend growth since its spinoff from Abbott Laboratories in 2013.
AbbVie has increased its dividend payout by an impressive 310% since its inception, earning a coveted spot in the S&P Dividend Aristocrats Index. This index recognises companies with at least 25 consecutive years of dividend increases, underscoring AbbVie's status as a reliable dividend growth stock.
Currently, AbbVie offers a dividend yield of approximately 3.45%, paying an annual dividend of about $6.56 per share on a quarterly basis (with $1.64 per quarter). This yield is attractive for income-focused investors looking for steady passive income.
The company's payout ratios are also sustainable. While AbbVie's payout ratio based on trailing earnings is high (over 270%), estimates for the next year suggest a more sustainable payout ratio ranging between 47% and 53% based on earnings and cash flow. This implies that the company generates sufficient earnings and cash flow to cover dividend payments, setting the stage for continued dividend growth.
AbbVie has demonstrated dividend growth rates between 5% to 12% in recent years, with a 5-year growth rate around 7.2%. Analysts and dividend investors expect this trend to continue, supported by AbbVie's stable cash generation and strategic position in the pharmaceutical industry.
Outside of Humira, AbbVie's immunology segment is expected to see significant growth. Combined sales of Skyrizi and Rinvoq are projected to grow roughly 226% from 2021 to reach over $15 billion in 2025. This diversification is part of AbbVie's strategy to prepare for competition from biosimilars and the expiration of most of the patents on Humira in 2034.
For investors, this growth potential coupled with the current dividend yield presents an opportunity. Based on AbbVie's payout growth history, investors could generate substantially more than $2,000 in passive income across a five-year stretch with a $10,000 initial investment at today's prices. Furthermore, reinvesting AbbVie's dividends would net an investor an extra 2.8 shares of the company by next year, setting up a compounding effect.
In summary, AbbVie’s impressive dividend growth history, solid yield, sustainable payout ratios, and strong business fundamentals position it well for continuing to generate passive income over the next five years. Investors can expect both reliable dividend payments and the potential for dividend increases, making AbbVie an attractive dividend growth stock for income-oriented portfolios.
AbbVie, with its impressive 310% increase in dividend payout since inception, offers a yield of approximately 3.45%, providing an appealing source of steady passive income for income-focused investors. The company's strategic focus on expanding its immunology segment, as seen in the projected growth of Skyrizi and Rinvoq, further strengthens its position as a reliable investment choice in the realm of personal-finance and business. By capitalizing on AbbVie's dividend growth potential and its inclusion in the S&P Dividend Aristocrats Index, investors could potentially reap substantial passive income, with a $10,000 initial investment potentially generating more than $2,000 across a five-year stretch, given its history of payout growth and sustainable ratios.
